GNS.L vs PAHC
GNS.L: A global leader in animal genetics, using biotechnology to improve the quality and efficiency of livestock production. PAHC: Phibro manufactures and distributes nutritional additives, pharmaceutical products, and specialty ingredients for animal health and nutritional enhancement worldwide.
Side-by-side fundamentals
| Metric | GNS.L | PAHC | Edge |
|---|---|---|---|
| Price as of 2026-08-03 close | £22.10 | $36.01 | |
| Market cap as of 2026-08-06 | n/a | $1.5B | |
| P/E as of 2026-08-06 | n/a | 15.59 | |
| PEG as of 2026-08-06 | n/a | 0.74 | |
| Net margin as of 2026-08-06 | n/a | +6.3% | |
| Gross margin as of 2026-08-06 | n/a | +32.8% | |
| Operating margin as of 2026-08-06 | n/a | +12.0% | |
| ROE as of 2026-08-06 | n/a | +29.5% | |
| ROA as of 2026-08-06 | n/a | +6.8% | |
| Debt / equity as of 2026-08-06 | n/a | 2.03 | |
| Revenue growth (YoY) as of 2026-08-06 | n/a | +26.0% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +11.2% | |
| Dividend yield as of 2026-08-06 | n/a | +1.3% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-06 | n/a | 0.41 | |
| 1-year return as of 2026-08-03 close | -11.2% | +35.4% | PAHC higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-03.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.